Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OPTN Stock Summary
Top 10 Correlated ETFs
OPTN
In the News
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held March 7, 2024, at 8:00 a.m. Eastern Time
OptiNose (OPTN) Upgraded to Buy: What Does It Mean for the Stock?
OptiNose (OPTN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Optinose to Present at the 2023 Cantor Global Healthcare Conference
YARDLEY, Pa., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023 Cantor Global Healthcare Conference on September 27, 2023 at 4:45 p.m. ET.
5 Top-Ranked Stocks With Rising P/E for Solid Returns
Tap five stocks with increasing P/E ratios to try out a different approach. These stocks include Nektar Therapeutics (NKTR), Energous (WATT), DocuSign (DOCU), OptiNose (OPTN) and Canadian Solar (CSIQ).
OptiNose (OPTN) Q2 Earnings and Revenues Top Estimates
OptiNose (OPTN) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share. This compares to loss of $0.23 per share a year ago.
OptiNose: The Worst Has Been Avoided (Rating Upgrade)
On August 10, OptiNose, one of the leaders in the global chronic rhinosinusitis market, will publish its financial results for the 2nd quarter of 2023. OptiNose's preliminary net revenue for the second quarter of 2023 was $19.5 million, up 65.3% from the previous quarter and down 5.4% from the first quarter of 2022. On May 4, 2023, the company announced that the FDA had accepted a supplemental new drug application seeking approval for Xhance as a treatment for chronic sinusitis.
Optinose to Present at the Jefferies Healthcare Conference
YARDLEY, Pa., June 02, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET.
OptiNose Inc. (OPTN) Q1 2023 Earnings Call Transcript
OptiNose Inc. (NASDAQ:OPTN ) Q1 2023 Results Conference Call May 11, 2023 8:00 AM ET Company Participants Jonathan Neely - VP of IR and Business Operations Ramy Mahmoud - CEO and Director Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose's First Quarter 2023 Earnings Conference Call.
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OptiNose (OPTN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.31 per share a year ago.
OPTN Financial details
OPTN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.83 | 1.02 | 1.31 | 0.89 | 0.63 | |
Net income per share | -2.6 | -2.04 | -1.44 | -0.89 | -0.32 | |
Operating cash flow per share | -2.17 | -1.79 | -1.35 | -0.79 | -0.18 | |
Free cash flow per share | -2.18 | -1.8 | -1.36 | -0.79 | -0.19 | |
Cash per share | 3.51 | 2.99 | 1.94 | 1.1 | 0.66 | |
Book value per share | 1.47 | 0.14 | -0.38 | -0.66 | -0.77 | |
Tangible book value per share | 1.47 | 0.14 | -0.38 | -0.66 | -0.77 | |
Share holders equity per share | 1.47 | 0.14 | -0.38 | -0.66 | -0.77 | |
Interest debt per share | 2.04 | 2.91 | 2.58 | 1.72 | 1.35 | |
Market cap | 386.11M | 199.86M | 92.1M | 158.92M | 144.58M | |
Enterprise value | 313.5M | 180.91M | 112.3M | 195.84M | 202.65M | |
P/E ratio | -3.54 | -2.03 | -1.13 | -2.08 | -4.07 | |
Price to sales ratio | 11.15 | 4.07 | 1.23 | 2.08 | 2.04 | |
POCF ratio | -4.25 | -2.32 | -1.2 | -2.35 | -7.04 | |
PFCF ratio | -4.23 | -2.3 | -1.19 | -2.35 | -6.93 | |
P/B Ratio | 6.27 | 29.44 | -4.23 | -2.81 | -1.67 | |
PTB ratio | 6.27 | 29.44 | -4.23 | -2.81 | -1.67 | |
EV to sales | 9.05 | 3.68 | 1.5 | 2.57 | 2.85 | |
Enterprise value over EBITDA | -3.28 | -2.07 | -1.69 | -3.5 | -9.07 | |
EV to operating cash flow | -3.45 | -2.1 | -1.46 | -2.89 | -9.87 | |
EV to free cash flow | -3.43 | -2.09 | -1.46 | -2.89 | -9.71 | |
Earnings yield | -0.28 | -0.49 | -0.89 | -0.48 | -0.25 | |
Free cash flow yield | -0.24 | -0.43 | -0.84 | -0.43 | -0.14 | |
Debt to equity | 1.23 | 18.76 | -6 | -2.32 | -1.52 | |
Debt to assets | 0.44 | 0.67 | 0.79 | 0.91 | 1.22 | |
Net debt to EBITDA | 0.76 | 0.22 | -0.3 | -0.66 | -2.6 | |
Current ratio | 4.07 | 2.76 | 2.71 | 0.53 | 0.6 | |
Interest coverage | -9.93 | -6.71 | -4.16 | -3.32 | -1.16 | |
Income quality | 0.83 | 0.86 | 0.93 | 0.9 | 0.58 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.01 | -0.01 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.6 | 0.48 | 0.34 | 0.2 | 0.07 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.01 | 0 | 0 | 0.02 | |
Capex to revenue | -0.02 | -0.01 | 0 | 0 | 0 | |
Capex to depreciation | -0.5 | -0.38 | -0.26 | -0.12 | -0.82 | |
Stock based compensation to revenue | 0.28 | 0.21 | 0.13 | 0.12 | 0.07 | |
Graham number | 9.28 | 2.54 | 3.52 | 3.63 | 2.35 | |
ROIC | -0.68 | -0.63 | -0.58 | -0.74 | -0.5 | |
Return on tangible assets | -0.63 | -0.52 | -0.49 | -0.53 | -0.33 | |
Graham Net | 1.15 | -0.33 | -0.79 | -0.89 | -0.91 | |
Working capital | 111.01M | 91.98M | 101.14M | -84.49M | -71.19M | |
Tangible asset value | 61.58M | 6.79M | -21.77M | -56.62M | -86.61M | |
Net current asset value | 36.08M | -37.87M | -27.46M | -106.6M | -89M | |
Invested capital | 1.23 | 18.76 | -6 | -2.32 | -1.52 | |
Average receivables | 8.19M | 18.61M | 29.42M | 34.69M | 26.93M | |
Average payables | 5.37M | 4.56M | 6.75M | 6.65M | 4.59M | |
Average inventory | 5.31M | 6.26M | 10.44M | 10.65M | 8.75M | |
Days sales outstanding | 145.64 | 173.85 | 173.32 | 162.37 | 102.46 | |
Days payables outstanding | 249.93 | 266.42 | 319.61 | 208.49 | 156.99 | |
Days of inventory on hand | 240.21 | 438.87 | 472.53 | 372.09 | 325.29 | |
Receivables turnover | 2.51 | 2.1 | 2.11 | 2.25 | 3.56 | |
Payables turnover | 1.46 | 1.37 | 1.14 | 1.75 | 2.33 | |
Inventory turnover | 1.52 | 0.83 | 0.77 | 0.98 | 1.12 | |
ROE | -1.77 | -14.49 | 3.75 | 1.35 | 0.41 | |
Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.22 | 0.11 | 0.17 | 0.18 | 0.18 | |
Net income per share | -0.18 | -0.17 | 0.02 | -0.08 | -0.09 | |
Operating cash flow per share | -0.19 | -0.09 | -0.11 | -0.04 | 0.06 | |
Free cash flow per share | -0.19 | -0.09 | -0.11 | -0.04 | 0.06 | |
Cash per share | 0.99 | 0.75 | 0.64 | 0.6 | 0.66 | |
Book value per share | -0.6 | -0.66 | -0.62 | -0.69 | -0.77 | |
Tangible book value per share | -0.6 | -0.66 | -0.62 | -0.69 | -0.77 | |
Share holders equity per share | -0.6 | -0.66 | -0.62 | -0.69 | -0.77 | |
Interest debt per share | 1.43 | 1.21 | 1.21 | 1.21 | 1.22 | |
Market cap | 175.68M | 215.72M | 137.74M | 138.04M | 144.88M | |
Enterprise value | 212.6M | 262.42M | 197.22M | 202.14M | 202.95M | |
P/E ratio | -2.53 | -2.89 | 13.11 | -3.71 | -3.63 | |
Price to sales ratio | 8.42 | 18.21 | 7.08 | 6.96 | 7.29 | |
POCF ratio | -9.94 | -20.59 | -10.99 | -31.2 | 20.97 | |
PFCF ratio | -9.93 | -20.59 | -10.92 | -30 | 21.19 | |
P/B Ratio | -3.1 | -2.92 | -1.98 | -1.78 | -1.67 | |
PTB ratio | -3.1 | -2.92 | -1.98 | -1.78 | -1.67 | |
EV to sales | 10.19 | 22.15 | 10.14 | 10.2 | 10.22 | |
Enterprise value over EBITDA | -25.44 | -18.26 | -47.27 | -119.33 | -84.88 | |
EV to operating cash flow | -12.03 | -25.04 | -15.73 | -45.68 | 29.37 | |
EV to free cash flow | -12.02 | -25.04 | -15.63 | -43.93 | 29.69 | |
Earnings yield | -0.1 | -0.09 | 0.02 | -0.07 | -0.07 | |
Free cash flow yield | -0.1 | -0.05 | -0.09 | -0.03 | 0.05 | |
Debt to equity | -2.32 | -1.77 | -1.88 | -1.69 | -1.52 | |
Debt to assets | 0.91 | 1.14 | 1.23 | 1.29 | 1.22 | |
Net debt to EBITDA | -4.42 | -3.25 | -14.26 | -37.84 | -24.28 | |
Current ratio | 0.53 | 0.5 | 0.63 | 0.6 | 0.6 | |
Interest coverage | -1.87 | -3.08 | -0.86 | -0.34 | -0.49 | |
Income quality | 1.17 | 0.56 | -4.78 | 0.48 | -0.69 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.14 | 0.15 | 0.05 | 0.06 | 0.06 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0.04 | -0.01 | |
Capex to revenue | 0 | 0 | 0 | -0.01 | 0 | |
Capex to depreciation | -0.02 | 0 | -0.74 | -1.71 | -0.6 | |
Stock based compensation to revenue | 0.07 | 0.13 | 0.08 | 0.06 | 0.05 | |
Graham number | 1.56 | 1.57 | 0.57 | 1.14 | 1.24 | |
ROIC | -0.12 | -0.24 | -0.07 | -0.03 | -0.06 | |
Return on tangible assets | -0.12 | -0.16 | 0.02 | -0.09 | -0.09 | |
Graham Net | -0.8 | -0.79 | -0.75 | -0.82 | -0.91 | |
Working capital | -84.49M | -82.38M | -60.69M | -65.36M | -71.19M | |
Tangible asset value | -56.62M | -73.79M | -69.66M | -77.62M | -86.61M | |
Net current asset value | -106.6M | -104.78M | -72.12M | -80.4M | -89M | |
Invested capital | -2.32 | -1.77 | -1.88 | -1.69 | -1.52 | |
Average receivables | 30.27M | 25.46M | 19.55M | 21.75M | 20.65M | |
Average payables | 6.85M | 5.77M | 6.36M | 5.74M | 4.45M | |
Average inventory | 9.93M | 8.87M | 8.02M | 7.89M | 8.05M | |
Days sales outstanding | 146.43 | 129 | 102.37 | 97.04 | 90.28 | |
Days payables outstanding | 159.74 | 329.4 | 226.91 | 202.49 | 155.3 | |
Days of inventory on hand | 285.1 | 438.02 | 270.67 | 325.33 | 321.79 | |
Receivables turnover | 0.61 | 0.7 | 0.88 | 0.93 | 1 | |
Payables turnover | 0.56 | 0.27 | 0.4 | 0.44 | 0.58 | |
Inventory turnover | 0.32 | 0.21 | 0.33 | 0.28 | 0.28 | |
ROE | 0.31 | 0.25 | -0.04 | 0.12 | 0.12 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
OPTN Frequently Asked Questions
What is OptiNose, Inc. stock symbol ?
OptiNose, Inc. is a US stock , located in Yardley of Pa and trading under the symbol OPTN
Is OptiNose, Inc. buy or a sell ?
2 stock analysts have 2 predictions with a medium analyst target price of $4.5. The lowest prediction is $4 and the highest is $5
What is OPTN stock prediction ?
What is OptiNose, Inc. stock quote today ?
OptiNose, Inc. stock price is $1.46 today.
Is OptiNose, Inc. stock public?
Yes, OptiNose, Inc. is a publicly traded company.